The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value
Open accessAbstract
SF3B1 mutations were recently reported in myelodysplastic syndromes (MDSs), especially in the presence of ring sideroblasts (RSs). We sought to define the interaction between SF3B1 mutations, morphology, karyotype, and prognosis in MDS with more than or equal to 15% RS (MDS-RS). We studied 107 patients with MDS-RS, including 48 with refractory anemia with RS (RARS), 43 with refractory cytopenia with multilineage dysplasia (RCMD)-RS, 11 with refractory anemia with excess blasts-1 (RAEB1)–RS, and 5 with RAEB2-RS. SF3B1 mutations were detected in 53 (∼ 50%) patients: 35 RARS (73%), 16 RCMD-RS (37%), and 2 RAEB1-RS (18%). In univariate analysis, the presence of SF3B1 mutations was associated with better overall (P < .01) and leukemia-free (P < .01) survival; however, in both instances, significance was completely accounted for by World Health Organization morphologic risk categorization. In other words, when RARS and RCMD-RS were analyzed separately, there was no additional prognostic value from the presence or absence of SF3B1 mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103283 · Cited by 1,222
Guernsey, D. L., Jiang, H., Campagna, D. R., Evans, S. C., Ferguson, M., Kellogg, M. D., Lachance, M., Matsuoka, M., Nightingale, M., Rideout, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.359 · Cited by 244 · cited 1×
“0001 RARS 48 (49) 35 (66) 13 (24) RCMD 43 (40) 16 (30) 27 (50) MDS-U 0 (0) 0 (0) 0 (0) RAEB-1 11 (10) 2 (4) 9 (17) RAEB-2 5 (5) 0 (0) 5 (9) Mutational analysis, n (%)”
Pellagatti, A. (2006) · Blood · doi:10.1182/blood-2005-12-4769 · Cited by 209 · cited 1×
“4 Platelets, 109 /L, median (range) 179 (6-585) 232 (14-585) 108 (6-484) .”
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts
Malcovati, L., Karimi, M., Papaemmanuil, E., Ambaglio, I., Jädersten, M., Jansson, M., Elena, C., Gallì, A., Walldin, G., Della Porta, M. G., et al. (2015) · Blood · doi:10.1182/blood-2015-03-633537 · Cited by 434
Thol, F., Kade, S., Schlarmann, C., Löffeld, P., Morgan, M., Krauter, J., Wlodarski, M. W., Kölking, B., Wichmann, M., Görlich, K., et al. (2012) · Blood · doi:10.1182/blood-2011-12-399337 · Cited by 419
The spliceosome as a target of novel antitumour drugs
Bonnal, S., Vigevani, L., & Valcárcel, J. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3823 · Cited by 405
Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis
Makishima, H., Visconte, V., Sakaguchi, H., Jankowska, A. M., Abu Kar, S., Jerez, A., Przychodzen, B., Bupathi, M., Guinta, K., Afable, M. G., et al. (2012) · Blood · doi:10.1182/blood-2011-12-399774 · Cited by 370
Metadata
- Authors
- Patnaik, M. M., Lasho, T. L., Hodnefield, J. M., Knudson, R. A., Ketterling, R. P., Garcia-Manero, G., Steensma, D. P., Pardanani, A., Hanson, C. A., & Tefferi, A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2012-01-12
- Volume
- 119
- Issue
- 2
- Pages
- 569-572
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2005150790
- Cited by
- 202
- References
- 5
- FWCI
- 14.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. https://app.cochat.ai/papers/10.1182/blood-2011-09-377994
- The paper
- Patnaik, M. M., Lasho, T. L., Hodnefield, J. M., Knudson, R. A., Ketterling, R. P., Garcia-Manero, G., Steensma, D. P., Pardanani, A., Hanson, C. A., & Tefferi, A. (2012). SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. https://doi.org/10.1182/blood-2011-09-377994
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.